KAPA — Kairos Pharma, Ltd.
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: New York Stock Exchange Arca
- Employees: 1
- Website: https://kairospharma.com
Latest SEC filings for KAPA
- 8-K — 2026-09-14
- 8-K — 2026-08-21
- 10-Q — 2026-08-12
- 8-K — 2026-07-22
- 8-K — 2026-07-15
- 8-K — 2026-06-30
- 8-K — 2026-06-04
- ARS — 2026-05-22
- 8-K — 2026-05-18
- 10-Q — 2026-05-13
Latest KAPA news
- — Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer (benzinga.com)
- — What's Moving Biotech Stocks Pre-Market? Bluejay Diagnostics (NASDAQ:BJDX), Kairos Pharma (NYSE:KAPA), Rezolute (NASDAQ:RZLT) in Focus - kalkine.ca (kalkine.ca)
- — Kairos Pharma Reports Strong Interim Results for ENV-105 Combo - TipRanks (TipRanks)
- — Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
Educational tool only — not investment advice.